Mumbai, Maharashtra Dec 24, 2021 (Issuewire.com) - Urolife Pharmaceuticals is a Private incorporated on 01-01-2001. It is classified as a Non-govt company and is registered at Registrar of Companies, Mumbai.
Its authorized share capital is ₹ 510,000,000 and its paid-up capital is ₹ 430,307,808. It is involved in Other wholesale [Includes specialized wholesale not covered in any one of the previous categories and wholesale in a variety of goods without any particular specialization]
Urolife Pharmaceuticals Annual General Meeting (AGM) was last held on 15 February 2021 and as per records from the Ministry of Corporate Affairs (MCA), its balance sheet was last filed on 31 March 2020.
Directors of Urolife Pharmaceuticals is Muzammil Rasool
Urolife Pharmaceuticals and its registration number are 43106.
In order to contact Urolife Pharmaceuticals - Mail them at:
urolifepharmaceutical@gmail.com
Website
and its registered address is Unit No. 5526 Vibgyor Towers, Bandra Kurla Complex, Bandra East, Mumbai Mumbai City MH 40008 IN
Who is the Director of Urolife Pharmaceuticals Private Limited?
What is Pharmaceutical Industry?
The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered (or self-administered) to patients, with the aim to cure them, vaccinate them, or alleviate the symptoms.
Pharmaceutical companies may deal in generic or brand medications and medical devices. They are subject to a variety of laws and regulations that govern the patenting, testing, safety, efficacy, and marketing of drugs. The global pharmaceuticals market is expected to grow from $1228.45 billion in 2020 to $1250.24 billion in 2021 at a compound annual growth rate (CAGR) of 1.8%.
In 2011, global spending on prescription drugs topped $954 billion, even as growth slowed somewhat in Europe and North America. The United States accounts for more than a third of the global pharmaceutical market, with $340 billion in annual sales followed by the EU and Japan.
Emerging markets such as China, Russia, South Korea, and Mexico outpaced that market, growing a huge 81 percent.
The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best-selling were Enbrel and Remicade, respectively.
The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion), and Humira ($5.4 billion).
The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011.
The current status of Urolife Healthcare is - Active.
Media Contact
UROLIFE *****@GMAIL.COM http://www.urolifepharmaceutical.com
